Protocol Ledger

NCT05642325 · Phase III · COMPLETED

Vamikibart in Participants With Uveitic Macular Edema

Interventional Phase III clinical trial protocol NCT05642325 sponsored by Roche / Genentech in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-23 Enrollment: 256 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05642325
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)256 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05642325
Protocol FieldVerified Registry Value
NCT IdentifierNCT05642325
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment256 participants (ACTUAL)
Registered Start Date2023-03-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05642325
Hospital Research SiteLocationSite Profile
Retina Consultants of Orange CountyFullerton, CAOpen Hospital Dossier ->
UC Davis Comprehensive Cancer CenterSacramento, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI